| scholarly article | Q13442814 |
| P2093 | author name string | Michael Scott | |
| Fred Poordad | |||
| Naim Alkhouri | |||
| Carmen Landaverde | |||
| Jennifer Wells | |||
| Eric Lawitz | |||
| Angie Coste | |||
| Nicole Loo | |||
| Rossalynn Salcido | |||
| P2860 | cites work | Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks | Q40947776 |
| Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials | Q41025039 | ||
| Racial differences in the progression to cirrhosis and hepatocellular carcinoma in HCV-infected veterans | Q42203327 | ||
| ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. | Q42219325 | ||
| Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin | Q42225540 | ||
| Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin | Q42225545 | ||
| Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. | Q42243136 | ||
| Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. | Q51442516 | ||
| Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma | Q22305316 | ||
| The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
| Outcome of sustained virological responders with histologically advanced chronic hepatitis C. | Q34101701 | ||
| The natural history of hepatitis C. | Q35877892 | ||
| The high comorbidity burden of the hepatitis C virus infected population in the United States | Q35927970 | ||
| Natural history and predictors of disease severity in chronic hepatitis C. | Q36342881 | ||
| Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens | Q37116816 | ||
| Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan | Q38649797 | ||
| Hepatocellular Carcinoma Is the Most Common Indication for Liver Transplantation and Placement on the Waitlist in the United States | Q39066393 | ||
| Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis | Q40211449 | ||
| P433 | issue | 18 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | gastroenterology | Q120569 |
| ribavirin | Q421862 | ||
| ritonavir | Q422618 | ||
| paritaprevir | Q16824572 | ||
| dasabuvir | Q19462214 | ||
| ombitasvir | Q19598175 | ||
| ombitasvir/paritaprevir/ritonavir | Q19858657 | ||
| P304 | page(s) | 2229-2239 | |
| P577 | publication date | 2019-05-14 | |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients | |
| P478 | volume | 25 |
| Q98895257 | Clinical and Patient-Reported Outcomes of Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C Among Patients on Opioid Agonist Treatment: A Real-world Prospective Cohort Study | cites work | P2860 |
Search more.